174 related articles for article (PubMed ID: 37958610)
21. K
Ohya S; Kajikuri J; Endo K; Kito H; Matsui M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948357
[TBL] [Abstract][Full Text] [Related]
22. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
23. [Downregulation of PTTG1 expression inhibits the proliferation and invasiveness and promotes the apoptosis of human prostate cancer LNCaP-AI cells].
Cao XL; Wei YY; Song XM; Lu KQ; Yu WC; Chen YQ; Liu YL; Gao JP
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):589-597. PubMed ID: 29723450
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.
Wang Y; Li JQ; Shao C; Shi CH; Liu F; Yang ZY; Qiu JX; Li YM; Fu Q; Zhang W; Xue W; Lei YH; Gao JY; Wang JY; Gao XP; Yuan JL; Bao TY; Zhang YT
Ir J Med Sci; 2011 Dec; 180(4):865-72. PubMed ID: 21748440
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
27. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
Suh H; Oh HL; Lee CH
J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
30. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
31. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
[TBL] [Abstract][Full Text] [Related]
32. The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Dotan N; Wasser SP; Mahajna J
Integr Cancer Ther; 2011 Jun; 10(2):148-59. PubMed ID: 21147815
[TBL] [Abstract][Full Text] [Related]
33. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D; Mendelsohn J; Fan Z
Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
Konduri S; Schwarz MA; Cafasso D; Schwarz RE
J Surg Res; 2007 Oct; 142(2):378-86. PubMed ID: 17559882
[TBL] [Abstract][Full Text] [Related]
35. Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Wang H; Wei X; Zhang D; Li W; Hu Y
BMC Mol Cell Biol; 2022 Nov; 23(1):51. PubMed ID: 36443669
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
37. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Bologna M; Muzi P; Biordi L; Festuccia C; Vicentini C
Urology; 1995 Feb; 45(2):282-90. PubMed ID: 7855976
[TBL] [Abstract][Full Text] [Related]
38. Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
Suh JH; Chattopadhyay A; Sieglaff DH; Storer Samaniego C; Cox MB; Webb P
PLoS One; 2015; 10(9):e0137103. PubMed ID: 26332122
[TBL] [Abstract][Full Text] [Related]
39. Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.
Tong da Y; Wu Xy; Sun Hy; Jin Y; Liu Zw; Zhou Fj
Tumour Biol; 2012 Dec; 33(6):2151-8. PubMed ID: 22935919
[TBL] [Abstract][Full Text] [Related]
40. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients.
Goda R; Nagai D; Akiyama Y; Nishikawa K; Ikemoto I; Aizawa Y; Nagata K; Yamazoe Y
Drug Metab Dispos; 2006 May; 34(5):828-35. PubMed ID: 16507648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
